Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Infectious Diseases

• Publication date

  2000-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/315312PMID 10720551
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

  1999cited by this paper
• Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.

  1999influential reference
• Microbiology of sputum from patients at cystic fibrosis centers in the United States.

  1998cited by this paper
• Aminoglycoside 6′-N-Acetyltransferase Variants of the Ib Type with Altered Substrate Profile in Clinical Isolates of Enterobacter cloacae and Citrobacter freundii

  1998cited by this paper
• Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings.

  1997cited by this paper
• Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation.

  1996cited by this paper
• Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

  1996cited by this paper
• The most frequently occurring aminoglycoside resistance mechanisms--combined results of surveys in eight regions of the world. The Aminoglycoside Resistance Study Groups.

  1995cited by this paper
• PCR mapping of integrons reveals several novel combinations of resistance genes

  1995cited by this paper
• Mechanism of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

  1995cited by this paper
• Pseudomonas aeruginosa corneal ulcer isolates distinguished using the arbitrarily primed PCR DNA fingerprinting method.

  1994influential reference
• Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes.

  1993cited by this paper
• Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolates

  1991cited by this paper
• Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis

  1980cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper

• Prevention of chronic pneumonia in children with severe motor and intellectual disabilities by long-term tobramycin inhalation: Its benefits and limitations.

  2025cites this paper
• Repression of resistance mechanisms of Pseudomonas aeruginosa: implications of the combination of antibiotics and phytoconstituents

  2024cites this paper
• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

  2023cites this paper
• Restoring susceptibility to aminoglycosides: identifying small molecule inhibitors of enzymatic inactivation.

  2023cites this paper
• Altering the viscoelastic properties of mucus-grown Pseudomonas aeruginosa biofilms affects antibiotic susceptibility

  2023cites this paper
• Aminoglycoside-Modifying Enzymes Are Sufficient to Make Pseudomonas aeruginosa Clinically Resistant to Key Antibiotics

  2022cites this paper
• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

  2022cites this paper
• Antibiotic Resistance in Pseudomonas.

  2022cites this paper
• Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa

  2022cites this paper
• Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: A systematic review and meta-analysis.

  2022cites this paper
• Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.

  2022cites this paper
• Interplay between biofilm microenvironment and pathogenicity of Pseudomonas aeruginosa in cystic fibrosis lung chronic infection

  2022cites this paper
• The Building Blocks of Antimicrobial Resistance in Pseudomonas aeruginosa: Implications for Current Resistance-Breaking Therapies

  2021cites this paper
• Chemotherapy and Mechanisms of Action of Antimicrobial Agent

  2021cites this paper
• Acidic Microenvironment Determines Antibiotic Susceptibility and Biofilm Formation of Pseudomonas aeruginosa

  2021cites this paper
• Cystic Fibrosis Acidic Microenvironment Determines Antibiotic Susceptibility and Biofilm Formation of Pseudomonas aeruginosa

  2020cites this paper
• Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review

  2019cites this paper
• Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice

  2019cites this paper
• Can the quorum sensing inhibitor resveratrol function as an aminoglycoside antibiotic accelerant against Pseudomonas aeruginosa?

  2018cites this paper
• CONSUMPTION AND BACTERIAL RESISTANCE TO AMINOGLYCOSIDES AT SUDANESE UNIVERSITY HOSPITAL

  2018cites this paper
• Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.

  2018cites this paper
• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

  2018cites this paper
• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

  2017cites this paper
• Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges

  2017cites this paper
• Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas

  2017cites this paper
• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

  2017cites this paper
• Investigating the genetic basis of preservative resistance in an industrial Pseudomonas aeruginosa strain

  2017cites this paper
• The phenotypic, genotypic and transcriptomic characterisation of a novel Pseudomonas aeruginosa small colony variant isolated from a chronic murine infection model

  2017cites this paper
• Proteogenomics of Pseudomonas aeruginosa in Cystic Fibrosis Infections

  2017cites this paper
• Antibiotic resistant bacteria in natural environments within Kentucky.

  2016cites this paper
• Discovery, characterization and in vivo activity of pyocin SD2, a protein antibiotic from Pseudomonas aeruginosa

  2016cites this paper
• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.

  2016cites this paper
• Improved Biofilm Antimicrobial Activity of Polyethylene Glycol Conjugated Tobramycin Compared to Tobramycin in Pseudomonas aeruginosa Biofilms.

  2015cites this paper
• Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.

  2015cites this paper
• The cell wall amidase AmiB is essential for Pseudomonas aeruginosa cell division, drug resistance and viability

  2015cites this paper
• Regulation of the mexCD-oprJ multidrug efflux operon in Pseudomonas aeruginosa: characterization of the NfxB-EsrC repressor interaction

  2015cites this paper
• Pseudomonas aeruginosa - Pathogenesis and Pathogenic Mechanisms

  2015cites this paper
• The involvement of a putative two component system PA2797-PA2798 in P. aeruginosa aminoglycoside resistance

  2014cites this paper
• Pseudomonas Aeruginosa AmpR Transcriptional Regulatory Network

  2013cites this paper
• Rise and dissemination of aminoglycoside resistance: the aac(6′)-Ib paradigm

  2013influential citation
• Pseudomonas aeruginosa: phenotypic flexibility and antimicrobial resistance

  2013cites this paper
• Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis

  2012cites this paper
• Studies on the involvement of quorum sensing in the regulation of exopolysaccharide biosynthesis by Burkholderia cepacia complex isolates

  2012cites this paper
• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

  2012cites this paper
• Rate of Isolation and Trends of Antimicrobial Resistance of Multidrug Resistant Pseudomonas Aeruginosa from Otorrhea in Chronic Suppurative Otitis Media

  2012cites this paper
• Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective

  2012cites this paper
• Interactions of Cationic Antimicrobial Peptides with Bacterial Membranes and Biofilms

  2012cites this paper
• Global regulation of the Lon protease of Pseudomonas aeruginosa and its influence on ciprofloxacin resistance and virulence

  2012cites this paper
• Chromosomal Determinants of Aminoglycoside Resistance in Pseudomonas aeruginosa

  2012cites this paper
• STUDIES ON THE INVOLVEMENT OF QUORUM SENSING IN THE REGULATION OF EXOPOLYSACCHARIDE BIOSYNTHESIS BY BURKHOLDERIA CEPACIA COMPLEX ISOLATES

  2012cites this paper
• Creeping baselines and adaptive resistance to antibiotics.

  2011cites this paper
• Pseudomonas Aeruginosa: Resistance to the Max

  2011cites this paper
• Involvement of an ATP-Dependent Protease, PA0779/AsrA, in Inducing Heat Shock in Response to Tobramycin in Pseudomonas aeruginosa

  2011cites this paper
• Inhaled antibiotics for gram-negative respiratory infections.

  2011cites this paper
• Pseudomonas aeruginosa Biofilms in the Lungs of Cystic Fibrosis Patients

  2011cites this paper
• Inhaled antibiotics for long-term therapy in cystic fibrosis.

  2011cites this paper
• reeping baselines and adaptive resistance to antibiotics

  2011cites this paper
• Importance of Adaptive and Stepwise Changes in the Rise and Spread of Antimicrobial Resistance

  2011cites this paper
• Crystal structure of MexZ, a key repressor responsible for antibiotic resistance in Pseudomonas aeruginosa.

  2010cites this paper
• Aminoglycoside modifying enzymes.

  2010cites this paper
• Exploratory Study of the Prevalence and Clinical Significance of Tobramycin-Mediated Biofilm Induction in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

  2010cites this paper
• Pseudomonas aeruginosa biofilms in cystic fibrosis.

  2010cites this paper
• Rezistencija na antibiotike u Pseudomonas aeruginosa

  2010cites this paper
• Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms

  2010cites this paper
• Pseudomonas aeruginosa - a phenomenon of bacterial resistance.

  2009cites this paper
• Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

  2009cites this paper
• Efflux Unbalance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

  2009cites this paper
• Rezistencija na antibiotike u Pseudomonas aeruginosa

  2009cites this paper
• Cystic fibrosis infections: treatment strategies and prospects.

  2009cites this paper
• Antibiotic Resistance in Pseudomonas aeruginosa Strains with Increased Mutation Frequency Due to Inactivation of the DNA Oxidative Repair System

  2009cites this paper
• Adaptation des mécanismes de résistance par efflux actif chez les souches de pseudomonas aeruginosa dans la mucoviscidose

  2009cites this paper
• Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism.

  2009cites this paper
• CHROMOSOMAL ANTIBIOTIC RESISTANCE MECHANISMS IN PSEUDOMONAS AERUGINOSA AND NEISSERIA GONORRHOEAE

  2008cites this paper
• Resistance of Gram-Negative Bacilli to Antimicrobials

  2008cites this paper
• Cystic Fibrosis—Coping with Resistance

  2008cites this paper
• Clinical impact of the over-expression of efflux pump in nonfermentative Gram-negative bacilli, development of efflux pump inhibitors.

  2008cites this paper
• Antimicrobial resistance of bacterial strains isolated from respiratory tract of cystic fibrosis patients with CFTR I1234V mutation

  2007cites this paper
• Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature

  2007cites this paper
• Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.

  2007cites this paper
• Cumulative Effects of Several Nonenzymatic Mechanisms on the Resistance of Pseudomonas aeruginosa to Aminoglycosides

  2006cites this paper
• [Anti Pseudomonas aeruginosa antibiotic therapy in cystic fibrosis (exclusion of macrolides)].

  2006cites this paper
• Mechanism of Enhanced Activity of Liposome-Entrapped Aminoglycosides against Resistant Strains of Pseudomonas aeruginosa

  2006cites this paper
• Efflux-mediated antimicrobial resistance.

  2005cites this paper
• Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.

  2005cites this paper
• Structural studies of the O antigen biosynthetic enzymes from Pseudomonas aeruginosa

  2005cites this paper
• Aminoglycoside Resistance in Pseudomonas aeruginosa

  2005cites this paper
• Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa.

  2004cites this paper
• Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection.

  2003cites this paper
• Pathophysiology and management of pulmonary infections in cystic fibrosis.

  2003cites this paper
• Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times.

  2003cites this paper
• Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.

  2003cites this paper
• Nebulised anti-pseudomonal antibiotics for cystic fibrosis.

  2003cites this paper
• Nebulised anti-pseudomonal antibiotics for cystic fibrosis.

  2003cites this paper
• Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis.

  2003cites this paper
• Contribution of the MexXY Multidrug Transporter to Aminoglycoside Resistance in Pseudomonas aeruginosa Clinical Isolates

  2003cites this paper
• Severe Infections Caused by Pseudomonas Aeruginosa

  2003influential citation
• Treatment of Serious Pseudomonas Aeruginosa Infections

  2003cites this paper
• Differential Behaviour of Fluid Liposomes Toward Mammalian Epithelial Cells and Bacteria: Restriction of Fusion to Bacteria

  2002cites this paper
• Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis.

  2002cites this paper
• [Interpretive reading of the non-fermenting gram-negative bacilli antibiogram].

  2002cites this paper